Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

16

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor

6

Adrenergic receptor beta

6

Alpha-1a adrenergic receptor

6

Alpha-2a adrenergic receptor

6

Alpha-2b adrenergic receptor

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

16

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1950

6

1970

6

1984

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cardiac arrest

6

Hypotension

6

Neurogenic orthostatic hypotension

6

Parkinson's disease

6

Systemic inflammatory response syndrome

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

16

Preventing

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

10

CNS Non-penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hazard, R.|Larde, R.

6

Hoffman-La Roche

6

Endo Laboratories

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

16

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

16

FDA UNII

16

PUBCHEM

15

EPA CompTox

12

EVMPD

11

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

4

CARDIOVASCULAR SYSTEM

2

ALIMENTARY TRACT AND METABOLISM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-PARKINSON DRUGS

3

CARDIAC THERAPY

2

ANALGESICS

1

ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS

1

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DOPAMINERGIC AGENTS

3

CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

2

ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS

1

DRUGS USED IN ADDICTIVE DISORDERS

1

OPIOIDS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Dopa and dopa derivatives

3

Adrenergic and dopaminergic agents

2

Centrally acting antiobesity products

1

Drugs used in alcohol dependence

1

Natural opium alkaloids

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

13

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 16 results

First page disabled
Previous page disabled
1
Next page
Next page

Naltrexone

5S6W795CQM

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Opioid receptors; mu/kappa/delta

Conditions:

Alcohol addiction

Opioid dependence

Naltrexone is marketed as its hydrochloride salt, naltrexone hydrochloride, under the trade names Revia and Depade. A once-monthly extended-release injectable formulation is marketed under the trade name Vivitrol. VIVITROL is indicated for the treatm...

ent of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, κ, and δ receptors in the CNS, with the highest affinity for the μ receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-β-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug. Low dose naltrexone is an “off label” use of naltrexone. Normal naltrexone usage to break addictions is 50mg – 100mg. Usage of low dose naltrexone ranges in the area of 3 mg – 4.5 mg dosing and is prescribed in an oral pill form and is quite inexpensive. For people with multiple sclerosis, the dosage of LDN ranges from 1.5 to 4.5 ml per day.

LEVODOPA

46627O600J

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

NOREPINEPHRINE

X4W3ENH1CV

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1950

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor

Alpha-1a adrenergic receptor

Adrenergic receptor beta

Alpha-2a adrenergic receptor

Alpha-2b adrenergic receptor

Alpha-2c adrenergic receptor

Conditions:

Neurogenic orthostatic hypotension

Systemic inflammatory response syndrome

Norepinephrine (l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic catecholamine with multiple roles including as a hormone and a neurotransmitter. As a stress hormone, norepinephrine affects parts of the brain where attention and res...

ponding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle. Norepinephrine can also suppress neuroinflammation when released diffusely in the brain from the locus ceruleus. Norepinephrine may be used for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension. Norepinephrine performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells. Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy.If plasma volumes are not corrected, hypotension may recur when Norepinephrine is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g., decreased renal perfusion)with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported. Overdoses or conventional doses in hypersensitive persons (e.g., hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pallor, intense sweating, and vomiting.

NALTREXONE HYDROCHLORIDE DIHYDRATE

5P80UKS30B

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Opioid receptors; mu/kappa/delta

Conditions:

Alcohol addiction

Opioid dependence

Naltrexone is marketed as its hydrochloride salt, naltrexone hydrochloride, under the trade names Revia and Depade. A once-monthly extended-release injectable formulation is marketed under the trade name Vivitrol. VIVITROL is indicated for the treatm...

ent of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, κ, and δ receptors in the CNS, with the highest affinity for the μ receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-β-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug. Low dose naltrexone is an “off label” use of naltrexone. Normal naltrexone usage to break addictions is 50mg – 100mg. Usage of low dose naltrexone ranges in the area of 3 mg – 4.5 mg dosing and is prescribed in an oral pill form and is quite inexpensive. For people with multiple sclerosis, the dosage of LDN ranges from 1.5 to 4.5 ml per day.

NALTREXONE BENZOATE

E1D3136FZJ

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Opioid receptors; mu/kappa/delta

Conditions:

Alcohol addiction

Opioid dependence

Naltrexone is marketed as its hydrochloride salt, naltrexone hydrochloride, under the trade names Revia and Depade. A once-monthly extended-release injectable formulation is marketed under the trade name Vivitrol. VIVITROL is indicated for the treatm...

ent of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, κ, and δ receptors in the CNS, with the highest affinity for the μ receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-β-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug. Low dose naltrexone is an “off label” use of naltrexone. Normal naltrexone usage to break addictions is 50mg – 100mg. Usage of low dose naltrexone ranges in the area of 3 mg – 4.5 mg dosing and is prescribed in an oral pill form and is quite inexpensive. For people with multiple sclerosis, the dosage of LDN ranges from 1.5 to 4.5 ml per day.

Naltrexone hydrochloride

Z6375YW9SF

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Opioid receptors; mu/kappa/delta

Conditions:

Alcohol addiction

Opioid dependence

Naltrexone is marketed as its hydrochloride salt, naltrexone hydrochloride, under the trade names Revia and Depade. A once-monthly extended-release injectable formulation is marketed under the trade name Vivitrol. VIVITROL is indicated for the treatm...

ent of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. VIVITROL is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, κ, and δ receptors in the CNS, with the highest affinity for the μ receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-β-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug. Low dose naltrexone is an “off label” use of naltrexone. Normal naltrexone usage to break addictions is 50mg – 100mg. Usage of low dose naltrexone ranges in the area of 3 mg – 4.5 mg dosing and is prescribed in an oral pill form and is quite inexpensive. For people with multiple sclerosis, the dosage of LDN ranges from 1.5 to 4.5 ml per day.

BISMUTH SUBDOPATE

G69RN28K8B

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

FOSLEVODOPA

37NQZ0J76I

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA HYDROCHLORIDE

JFU1A8866V

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA

M30686U4X4

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

Showing 1 - 10 of 16 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1